You are here: Industry Insights > hepatitis B

News List

Arrowhead Begins Dosing in Phase 1/2 Study of ARO-HBV for Treatment of Chronic Hepatitis B biospace
March 28, 2018
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2 clinical study of ARO-HBV
Antiviral drug not beneficial for reducing mother-to-child transmission of hepatitis B europeanpharmaceuticalreview
March 12, 2018
Tenofovir disoproxil fumarate (TDF) does not significantly reduce mother-to-child transmission of hepatitis B virus when taken during pregnancy and after delivery.
First Chronic Hepatitis B Patient Dosed in China in a Phase I Trial of T101 (Transgene’s TG1050 Tech biospace
January 18, 2018
TRANSGENE SA (Paris: TNG) announced that the first patient conducted a phase 1 clinical trial in China to evaluate the efficacy of the T101 vaccine in immunotherapy of chronic hepatitis B virus (HBV) infection.
Researcher develop new treatment of chronic hepatitis B virus infection in human trials biospectrumasia
November 09, 2017
New treatment of chronic hepatitis B virus infection now in trials.
HKU researchers connect liver cancer with Hepatitis B biospectrumasia
September 22, 2017
The HKU study confirms the effectiveness of HBV treatment in reducing the burden of liver cancer.
GlaxoSmithKline taking heat in its U.K. home turf over shortages of hepatitis B vaccine fiercepharma
August 23, 2017
GSK has confirmed the global shortage of the vaccine but declined to comment on any alleged disparity of supplies favoring the U.S. over the U.K.
Global shortage of Hepatitis B vaccines : PHE biospectrumasia
August 10, 2017
Health officials have announced emergency measures to put a temporary restriction on who can have a hepatitis B vaccination, only the most vulnerable people will get an immediate shot of the vaccine
UK babies to be routinely immunised against hepatitis B pharmafile
August 02, 2017
As of today, all babies born in the UK will be administered with the vaccine for hepatitis B, with the jab being added to the five-in-one jab used for routine immunisations in newborns.
Janssen Enters Collaboration with Bavarian Nordic to Develop Vaccines Against Hepatitis B Virus and biospectrumasia
August 02, 2017
Collaboration to combine Janssen’s vaccine technologies with MVA-BN technology from Bavarian Nordic to advance potential new vaccine regimens.

Previous page 1 2 Next page